[ET Net News Agency, 24 March 2021] WuXi Biologics (Cayman) Inc. (02269) said its
profit attributable to equity shareholders of the company was RMB1,688.9 million for the
year ended 31 December 2020, a year-on-year increase of 66.6%. The basic earnings per
share were RMB0.43. No dividend will be distributed.
The revenue was RMB5,612.4 million, a year-on-year increase of 40.9%. (RC)